InVisionSeq™ is a qualitative laboratory developed test that uses targeted advanced sequencing technology to detect single nucleotide variants (SNVs), copy number variants (CNVs), insertions and deletions (InDels) in selected genes from DNA isolated from plasma samples from patients.

InVisionSeq™ is available world-wide for both commercial and research use for a range of cancer types. This test is not reimbursed in the US.

AKT1ALKBRAFCCND1CDKN2ACTNNB1
EGFRERBB2 (HER2)ESR1FGFR1FGFR2FGFR3
GATA3GNA11GNAQGNASHRASIDH1
IDH2KITKRASMAP2K1METMYC
NFE2L2NRASNTRK1NTRK3PDGFRAPIK3CA
PPP2R1APTENROS1STK11TP53U2AF1
SNVs + Indels - Hotspot Regions
SNVs + Indels - Exon Coverage 70% for PTEN, 88-100% for TP53, STK11 and CDKN2A
CNVs + SNVs + Indels
CNVs only

Our Technology

Our Solutions

Latest News